Global Blood Therapeutics Inc (NASDAQ:GBT): Steve Cohen’s Point72 Asset Management filed an amended 13D.
You can check out Point72 Asset Management’s latest holdings and filings here.
Please follow Point72 Asset Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Point72 Asset Management or update its stock holdings.
Follow Steve Cohen's Point72 Asset Management
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Point7 | 0 | 2,268,800 | 0 | 2,268,800 | 2,268,800 | 5.2% |
| Point7 | 0 | 2,268,800 | 0 | 2,268,800 | 2,268,800 | 5.2% |
| Cubist Systematic Strategies | 0 | 6,699 | 0 | 6,699 | 6,699 | Less than 0.1% |
| Point7 | 0 | 828 | 0 | 828 | 828 | Less than 0.1% |
| Steven A. Cohen | 0 | 2,276,327 | 0 | 2,276,327 | 2,276,327 | 5.2% |
Follow Steve Cohen's Point72 Asset Management
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 11 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
(Amendment No. )*
GLOBAL BLOOD THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, Par Value $0.001 Per Share
(Title of Class of Securities)
37890U108
(CUSIP Number)
October 2, 2017
(Date of Event which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) | |
| ☒ | Rule 13d-1(c) | |
| ☐ | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Global Blood Therapeutics Inc. (NASDAQ:GBT)
Follow Global Blood Therapeutics Inc. (NASDAQ:GBT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 11
